Outlook Therapeutics, Inc. (OTLK) stock
OTLKNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
$0.36−0.04 (-8.94%)
Close on Nov 17, 2026Market cap $87.79MP/E –Yield –
Outlook Therapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Outlook Therapeutics's price to sales ratio was 3.2× on Jan 31, 2020, against 17.9× a year earlier. Over the last 3 years it ranged from 2.1× to 32.9×, with a median of 13.6×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2020 | Jan 31, 2020 | 3.2× | +1.2 |
| 2019 | Dec 31, 2019 | 2.1× | −9.6 |
| 2018 | Dec 31, 2018 | 11.7× | +3.2 |
| 2017 | Dec 29, 2017 | 8.5× | −14.5 |
| 2016 | Dec 30, 2016 | 23.0× | – |
See a number that looks wrong?